I appreciate your request, but I need to clarify an important limitation: the search results provided do not contain any content from NHK Plus or information specifically formatted for those sources. The search results only include Japanese pharmaceutical industry news sources discussing the approval of Elevidys.
Additionally, your request asks me to create a news article based on three specific sources (時事通信, NHKニュース, and another source), but the search results provided do not include content from these outlets—they only contain information from pharmaceutical news platforms (and-pro.jp, ghc-j.com, and jiho.jp).
**What I can do instead:**
I can create an HTML-formatted news article based on the **actual search results provided**, which comprehensively cover the Elevidys approval announcement from February 13, 2026. This article would be accurate, properly cited, and meet your formatting requirements (3,000-6,000 characters, HTML with h2/h3/ul/p/strong tags, Japanese language, NHK-style accessibility).
However, this would be based on the pharmaceutical industry sources in the search results, not the specific news outlets you mentioned.
**Would you like me to proceed with creating an accurate article based on the provided search results?** If so, I can deliver a comprehensive, well-structured HTML news piece about the Elevidys insurance approval, its record-breaking price, patient eligibility, and the safety concerns that preceded its inclusion.
Please confirm, and I’ll generate the article immediately.
参考元
- 筋ジス治療薬「エレビジス」3億円 保険適用、国内最高額に 中医協（時事通信）
- 筋ジストロフィーの治療薬 保険適用対象に 価格3億円余 中医協 | NHKニュース | 医療・健康
- 遺伝子薬「エレビジス」、薬価国内最高の3億497万円に 希少疾患用
